PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Clinical trial NCT04038411 · UNKNOWN

Trial details

NCT number: NCT04038411
Sponsor: Mingzhi Zhang
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

NK/T Cell Lymphoma

Start date: 2019-04-01
Primary completion: 2021-04-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.